Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34⁺ Bone Marrow Mononuclear Cells

Table 1

Clinical trials of bone marrow cell (BMC) therapy by intracoronary delivery following acute ST-segment elevation MI (STEMI).

Study author; (trial name)	Date published	𝑁	Days after STEMI; (mean)	Primary outcome	Mean no. CD34^+cells; (millions)
Assmus et al., [10]; (TOPCARE-AMI)	2002	20	4	Improved LVEF	7.4
Fernandez-Aviles et al., [46]	2004	20	13	No difference	Not reported
Bartunek et al., [55]	2005	35	11.6	Improved LVEF	15.4
Ge et al., [15]; (TCT-STAMI)	2006	20	<1	Improved LVEF	0.1
Hirsch et al., [19]; (HEBE)	2011	200	5	No difference	4
Huikuri et al., [16]; (FINCELL)	2008	80	3	Improved LVEF	2.6
Janssens et al., [20]; (LEUVEN-AMI)	2006	67	<1	No difference	2.8
Lunde et al., [21]; (ASTAMI)	2006	97	6	No difference	0.7
Meluzín et al., [50]	2008	60	6.9	Improved LVEF	Not reported
Quyyumi et al., [39]; (AMR-001)	2011	31	8	Positive trend towards improved EF in highest dose group	5, 10, 15
Roncalli et al., [56]	2011	101	9.3	Improved myocardial viability	1.2
Schachinger et al., [17]; (REPAIR-AMI)	2006	204	4	Improved LVEF	3.6
Strauer et al., [6]	2002	10	7	No difference	<0.6
Tendera et al., [25]; (REGENT)	2009	200	7	No difference	1.9 (CD34^+ CXCR4^+ cell group), not reported for unselected cell group
Traverse et al., [23]	2010	40	5	No difference	1.6
Traverse et al., [22]; (LateTIME)	2011	87	17	No difference	3.8
Wollert et al., [13]; (BOOST)	2004	60	5	Improved LVEF	9.5